Prosecution Insights
Last updated: May 29, 2026

Janssen Pharmaceutica NV

28 pending office actions • 20 art units • 28 examiners • 0 of 28 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days

Portfolio Summary

28
Total Pending OAs
17
Non-Final OAs
9
Final Rejections
2
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 28 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

18
Overdue
1
Due this week
6
Due this month
3
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 28 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (18)Due ≤ 7 days (1)Due ≤ 30 days (6)Due ≤ 60 days (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (4%)
12
Medium (43%)
4
Easy (14%)
11
Unknown (39%)

Rejection Statute Mix

BucketCases
§101 only1 (4%)
§103 only11 (39%)
§102 only1 (4%)
§112 only4 (14%)
No statute on record11 (39%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

22
Life Sciences
79% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
6
Mechanical / Eng
21% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

280 h
Manual time on pending OAs
56 h
Time saved (low, 20%)
98 h
Time saved (mid, 35%)
2.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
RUIZ, JOSHUA DAMIAN 1 0.0% +0.0%
ROZOF, TIMOTHY R 1 72.6% +24.0%
JARRELL, NOBLE E 1 81.3% +9.0%
TRAN HO, LAM THUY VI 1
MCINTOSH III, TRAVISS C 1 73.3% +13.9%
KANAAN, LIZA TONY 1 22.4% +35.2%
SHIM, DAVID M. 1 58.8% +56.0%
CHICKS, ASHLI ARIANA 1 64.1% +44.9%
PECKHAM, RICHARD GRANT 1 68.3% +35.6%
WEIDNER, ADAM M 1 63.6% +33.9%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18558925 DIGITAL MEASUREMENT STACKS FOR CHARACTERIZING DISEASES, MEASURING INTERVENTIONS, OR DETERMINING OUTCOMES KANAAN, LIZA TONY 43d overdue
18873142 COLLABORATIVE FRAMEWORKS FOR IMPROVING REGULATORY DECISION-MAKING OF MEASUREMENT SOLUTIONS RUIZ, JOSHUA DAMIAN 30d overdue
18002527 SYSTEM AND METHOD FOR DETECTING OR PREDICTING RETURN IN MAJOR DEPRESSIVE DISORDER KOLOSOWSKI-GAGER, KATHERINE 20d

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18558925 DIGITAL MEASUREMENT STACKS FOR CHARACTERIZING DISEASES, MEASURING INTERVENTIONS, OR DETERMINING OUTCOMES KANAAN, LIZA TONY 43d overdue
18557346 MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 SHIM, DAVID M. 35d overdue
18546116 MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER PECKHAM, RICHARD GRANT 25d overdue
18548747 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 CHICKS, ASHLI ARIANA 23d overdue
18343689 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS WEIDNER, ADAM M 17d overdue
18560242 COMBINATION THERAPIES MCINTOSH III, TRAVISS C 9d
18649184 COMPOUNDS AND USES THEREOF ROZOF, TIMOTHY R 26d

Top Art Units

Art UnitApps
1647 3
1675 3
1626 2
1627 2
3783 2
1623 2
3684 1
1625 1
1699 1
1693 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18873142 COLLABORATIVE FRAMEWORKS FOR IMPROVING REGULATORY DECISION-MAKING OF MEASUREMENT SOLUTIONS RUIZ, JOSHUA DAMIAN 3684 §102 Non-Final OA 30d overdue Pending Dec 09, 2024
18649184 COMPOUNDS AND USES THEREOF ROZOF, TIMOTHY R 1625 Other Non-Final OA 26d Pending Apr 29, 2024
18528215 RAPAMYCIN ANALOGS AND USES THEREOF JARRELL, NOBLE E 1699 Other Non-Final OA 24d overdue Pending Dec 04, 2023
18561347 FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SOLID TUMORS TRAN HO, LAM THUY VI 1647 Other Non-Final OA 48d Pending Nov 16, 2023
18560242 COMBINATION THERAPIES MCINTOSH III, TRAVISS C 1693 Other Non-Final OA 9d Pending Nov 10, 2023
18558925 DIGITAL MEASUREMENT STACKS FOR CHARACTERIZING DISEASES, MEASURING INTERVENTIONS, OR DETERMINING OUTCOMES KANAAN, LIZA TONY 3683 §103 Final Rejection 43d overdue Pending Nov 03, 2023
18557346 MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS INHIBITORS OF MCL-1 SHIM, DAVID M. 1626 §112 Non-Final OA 35d overdue Pending Oct 26, 2023
18548747 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 CHICKS, ASHLI ARIANA 1626 §112 Non-Final OA 23d overdue Pending Sep 01, 2023
18546116 MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER PECKHAM, RICHARD GRANT 1627 §112 Non-Final OA 25d overdue Pending Aug 11, 2023
18343689 CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS WEIDNER, ADAM M 1675 Other Non-Final OA 17d overdue Pending Jun 28, 2023
18298580 Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations STIMPERT, PHILIP EARL 3783 §103 Non-Final OA 25d overdue Pending Apr 11, 2023
18044232 FGFR INHIBITOR COMBINATION THERAPIES VALLE, ERNESTO 1623 §103 Final Rejection 55d Pending Mar 07, 2023
18023643 DRUG DELIVERY DEVICES WITH A MULTI-DISPENSING HEAD ZIEGLER, MATTHEW D 3785 §103 Final Rejection 40d Pending Feb 27, 2023
18022910 DRUG SYRINGES WITH A MECHANICAL STOP FOR A SECOND DOSE AHMED, TASNIM M 3783 §103 Non-Final OA 7d Pending Feb 23, 2023
18154020 ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS ALLEN, MARIANNE P 1647 Other Final Rejection 181d overdue Pending Jan 12, 2023
18004464 LONG-ACTING FORMULATIONS BOATENG, AFUA BAMFOAA 1617 Other Non-Final OA 13d Pending Jan 06, 2023
18002527 SYSTEM AND METHOD FOR DETECTING OR PREDICTING RETURN IN MAJOR DEPRESSIVE DISORDER KOLOSOWSKI-GAGER, KATHERINE 3687 §101 Final Rejection 20d Pending Dec 20, 2022
18084092 BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer HERNANDEZ, JACKSON J 1627 Other Final Rejection 14d Pending Dec 19, 2022
18076567 CRYSTAL STRUCTURE OF BTK PROTEIN AND BINDING POCKETS THEREOF SCHULTZHAUS, JANNA NICOLE 1685 §103 Non-Final OA 23d overdue Pending Dec 07, 2022
17998198 TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB STOICA, ELLY GERALD 1647 §112 Final Rejection 20d Pending Nov 08, 2022
17998204 PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB RICCI, CRAIG D 1611 Other Non-Final OA 3d overdue Pending Nov 08, 2022
17736305 Formulations/Compositions Comprising a BTK Inhibitor BORI, IBRAHIM D 1629 §103 Final Rejection 18d overdue Pending May 04, 2022
17763251 USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS ALSOMAIRY, SARAH ABDOALATIF 1646 §103 Non-Final OA 78d overdue Pending Mar 24, 2022
17621377 BIORELEVANT DISSOLUTION MEDIA MAEWALL, SNIGDHA 1612 §103 Non-Final OA 79d overdue Pending Dec 21, 2021
17616248 NOVEL SPIROBICYCLIC INTERMEDIATES MCMILLIAN, KARA RENITA 1623 §103 Non-Final OA 42d overdue Pending Dec 03, 2021
17528050 Methods of Treating Prostate Cancer CORNET, JEAN P 1628 Other Non-Final OA 142d overdue Pending Nov 16, 2021
17509889 Methods of Reducing Tau in Human Subjects WANG, CHANG YU 1675 Other Non-Final OA 44d overdue Pending Oct 25, 2021
17477435 METHODS FOR TREATING MULTIPLE MYELOMA BENAVIDES, JENNIFER ANN 1675 §103 Final Rejection 4d overdue Pending Sep 16, 2021

Managing Janssen Pharmaceutica NV's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month